RxDoctor Payments Data

Sarah See, MD

Family Medicine · Kihei, HINPI 1932372265

Payments from drug & device makers

$985in general payments, 2019–2025

Across 47 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$202
  • Pfizer$183
  • Nxstage Medical, Inc.$175
  • AstraZeneca$146
  • AbbVie$94
  • Amgen$43
  • plus $141 from 6 others

What the payments were for

  • Food & beverage$86988%
  • Education$11612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk5$202
Pfizer12$183
Nxstage Medical, Inc.3$175
AstraZeneca11$146
AbbVie(2 entities)5$94
Amgen(2 entities)3$43
Merck3$37
Sanofi-aventis U.S. LLC1$24
Gilead1$24
Radius Health, Inc.1$22
GSK1$21
Teva Pharmaceuticals USA, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$985 in reported general payments places this provider in the 70th percentile of 376 family medicine providers in Hawaii.

See all family medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$48,531
Medicare patients
195
Services billed
522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$56,881
EliquisApixaban38$32,161
JanuviaSitagliptin Phosphate23$28,267
FarxigaDapagliflozin Propanediol19$27,765
XareltoRivaroxaban12$19,674
LinzessLinaclotide11$15,890
Dexlansoprazole DrDexlansoprazole16$5,632
Breo ElliptaFluticasone/Vilanterol12$4,713
SynthroidLevothyroxine Sodium62$3,944
Atorvastatin Calcium290$3,070
Celecoxib71$2,582
Esomeprazole Magnesium18$2,537
Losartan Potassium197$2,247
Metoprolol Succinate136$1,827
Alprazolam137$1,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$202$56,88135 claims
PfizerEliquis$183$32,16138 claims
MerckJanuvia$37$28,26723 claims
AstraZenecaFarxiga$146$27,76519 claims
AbbVieLinzess, Synthroid$94$19,83473 claims
GSKBreo Ellipta$21$4,71312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 376 family medicine providers in Hawaii.

Other family medicine in Kihei

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →